verve therapeutics eli lilly - Search News

News

Eli Lilly Buys Verve Therapeutics

The Motley Fool on MSN · 4h

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve. The deal centers on an exciting cardiovascular health medicine program,

Beyond Obesity: Eli Lilly’s Genetic Medicine Bet On Verve Therapeutics

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio.

The Wall Street Journal on MSN · 3d

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement, the pharmaceutical company will buy all of the gene-editing startup’s shares outstanding for $10.

3d

Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click ...

3d

Eli Lilly to buy Verve Therapeutics for up to $1.3 Billion

Eli Lilly is taking a big swing into gene editing with a deal to buy Verve (NASDAQ:VERV) Therapeutics for up to $1.3 billion, ...

3don MSN

This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly

Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results